고중성지방혈증에서 fenofibrate에 대한 acipimox의 효과 비교

키워드

참고문헌 (21)

1. Libby P, "Current concepts of the pathogenesis of the acute coronary syndromes", Circulation, 104, pp.365~372 (2001)
2. Castelli WP, "Epidemiology of coronary heart disease: the Framingham Study", Am J Med, 76, pp.4~12 (1984)
3. Neaton JD, "Serum cholesterol level and mortality findings for men screened in the Multiple Risk Factor Intervention Trial", Arch Intern Med, 152, pp.1490~1500 (1992)
4. Haffner SM, "Diabetes, hyperlipidemia, and coronary artery disease", Am J Cardiol, 83(9B), pp.17F~21F (1999)
5. Best JD, "Diabetic dyslipidaemia: current treatment recommendations", Drugs, 59, pp.1101~1111 (2000)
6. Taskinen MR, "Triglyceride is the major atherogenic lipid in NIDDM", Diabetes Metab, 13, pp.93~98 (1997)
7. Musatti L, "Bioavailability and pharmacokinetics in man of acipimox, a new antilipolytic and hypolipemic agent", J Int Med Res, 9, pp.381~386 (1981)
8. Lovisolo PP, "Pharmacological profile of a new anti-lipolytic agent: 5-methyl-pyrazine-2-carbozylic acid 4- oxide(Acipimox)(1)I-Mechanism of action", Pharmacol Res Commun, 13, pp.151~161 (1981)
9. Lovisolo PP, "Pharmacological profile of a new anti-lipolytic agent: 5-methyl-pyrazine-2-carbozylic acid 4-oxide (Acipimox) (1)II-Antilipolytic and blood lipid lowering activity", Pharmacol Res Commun, 13, pp.163~174 (1981)
10. Seed M, "The effect of nicotinic acid and acipimox on lipoprotein(a) concentration and turnover", Atherosclerosis, 101, pp.61~68 (1993)
11. Lintott CJ, "Treatment of hyperlipidaemia with acipimox", Curr Med Res Opin, 11, pp.374~379 (1989)
12. Saloranta C, "Different acute and chronic effects of acipimox treatment on glucose and lipid metabolism in patients with type 2 diabetes", Diabet Med, 10, pp.950~957 (1993)
13. Vaag AA, "Effects of prolonged acipimox treatment on glucose and lipid metabolism and on in vivo insulin sensitivity in patients with non-insulin dependent diabetes mellitus", Acta Endocrinol(Copenh), 127, pp.344~350 (1992)
14. Otto C, "Effects of acipimox on haemorheology and plasma lipoproteins in patients with mixed hyperlipoproteinaemia", Br J Clin Pharmacol, 46, pp.473~478 (1998)
15. Sirtori CR, "Reduced triglyceridemia and increased high density lipoprotein cholesterol levels after treatment with acipimox, a new inhibitor of lipolysis", Atherosclerosis, 38, pp.267~271 (1981)
16. Shin KC, "Acipimox attenuates hypertriglyceridemia in dyslipidemic noninsulin dependent diabetes mellitus patients without perturbation of insulin sensitivity and glycemic control", Diabetes Res Clin Pract, 36, pp.113~119 (1997)
17. Guay DR, "Micronized fenofibrate: a new fibric acid hypolipidemic agent", Ann Pharmacother, 33, pp.1083~1103 (1999)
18. Munoz A, "Micronized fenofibrate", Atherosclerosis, 110(Suppl), pp.S45~S48 (1994)
19. Shepherd J, "Mechanism of action of fibrates", Postgrad Med J, 69(Suppl1), pp.S34~S41 (1993)
20. Austin MA, "Hypertriglyceridemia as a cardiovascular risk factor", Am J Cardiol, 81(4A), pp.7B~12B (1998)
21. 김성옥, "고혈압과 당뇨병 노인의 복약순응도와 이에 영향을 미치는 요인", 한국임상약학회지, 21(2), pp.81~89 (2011), 한국임상약학회

관련 논문AI추천